Growth hormone co-treatment in IVF/ICSI cycles in poor responders

Ksenia Ob’edkova, Igor Kogan, Inna Krikheli, Lyailya Dzhemlikhanova, Valeria Muller, Irina Mekina, Elena Lesik, Evgenia Komarova, Maria Mazilina, Dariko Niauri, Alexandr Gzgzyan, Edward Aylamazyan

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


To estimate the efficacy of growth hormone (GH) co-treatment within an antagonist protocol in IVF/ICSI cycles in poor responders. A prospective observational study involving 50 patients underwent a standard antagonist protocol with or without GH co-treatment. GH was administered by a daily subcutaneous injection of 1,33 mg (equivalent to 4 IU) starting from day 1 of ovarian stimulation until the day of 10,000 human chorionic gonadotropin (hCG) triggering. Concentrations of GH, insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) in serum and follicular fluid were the subject matter of analysis. The GH co-treatment significantly lowered the effective dose of gonadotropins, duration of stimulation, IGFBP-3 level in serum and follicular fluid on the day of oocyte retrieval. The total number of oocytes as well as the number of metaphase II stage (MII) oocytes, two pronucleus (2 pn) zygotes, good-quality transferred embryos was significantly higher in the GH + group. Pregnancy was achieved in patients GH + group only. Positive correlation was found between IGF-I level in follicular fluid, dynamics of IGFBP-3 level changes during stimulation protocol and the number of good-quality transferred embryos in the GH + group. GH administration in IVF/ICSI cycles for poor responders raises ovarian sensitivity to the gonadotropin exogenous influence, increasing number of high-quality embryos and the probability of pregnancy.

Translated title of the contributionДополнительная терапия препаратами гормона роста в программах ЭКО/ИКСИ у пациенток с "бедным ответом"
Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalGynecological Endocrinology
Issue numbersupl 1
StatePublished - 22 Dec 2017

Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Obstetrics and Gynecology


  • assisted reproductive technologies
  • Growth hormone
  • in vitro fertilization
  • poor ovarian response


Dive into the research topics of 'Growth hormone co-treatment in IVF/ICSI cycles in poor responders'. Together they form a unique fingerprint.

Cite this